Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment.

[1]  I. Burger,et al.  Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[3]  Charles Ferté,et al.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.

[4]  M. Burotto,et al.  Pseudoprogression and Immune-Related Response in Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.